Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Polyrizon Ltd. - Ordinary Shares
(NQ:
PLRZ
)
1.570
-0.760 (-32.62%)
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 20, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Polyrizon Ltd. - Ordinary Shares
Polyrizon Appoints Dr. Michal Meir as Senior Director of Regulatory and Clinical Affairs
December 19, 2024
From
Polyrizon Ltd.
Via
GlobeNewswire
Polyrizon's Moving Forward with Expected 2025 Clinical Trial - Entered Manufacturing Agreement for its PL-14 Allergy Blocker
December 18, 2024
From
Polyrizon Ltd.
Via
GlobeNewswire
Polyrizon Announces Appointment of VP of Regulatory Affairs and Quality Assurance
December 13, 2024
From
Polyrizon Ltd.
Via
GlobeNewswire
Polyrizon Enters into GMP Manufacturing Agreement for CTM Supply of its PL-14 Allergy Blocker in Preparation for Planned 2025 Clinical Trial
December 02, 2024
From
Polyrizon Ltd.
Via
GlobeNewswire
BioMedNewsBreaks — Polyrizon Ltd. (NASDAQ: PLRZ) Secures $4.2M in Initial Public Offering
October 30, 2024
Via
Investor Brand Network
Aegis Capital Corp. Acted as Sole Bookrunner on a $4.2 Million (IPO) Initial Public Offering for Polyrizon Ltd. (NASDAQ: PLRZ)
October 30, 2024
Via
ACCESSWIRE
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.